Long-term safety of
adalimumab in
psoriasis clinical studies has been established. The objective of this research was to review real-world evidence of
adalimumab safety from registries of adult patients with
psoriasis treated in clinical practice. Databases (BIOSIS Previews, Current Contents Search, Derwent Drug File, EMBASE, EMBASE Alert, EMCare, MEDLINE, SciSearch) were searched for
psoriasis registries with
adalimumab safety data. Eligible papers were English language manuscripts (conference abstracts excluded) from
psoriasis registries presenting safety data for adult patients with
psoriasis receiving
adalimumab. The incidence and rate (events/100 patient-years [PY]) of adverse events (AEs), serious AEs (SAEs) and AEs of special interest are reported. Abstracts of 425 publications were screened, and 401 publications excluded (208 conference abstracts; 193 papers). Remaining manuscripts were fully screened; 14 were excluded (no
adalimumab data, n = 10; no safety data, n = 2; no on-treatment data, n = 1; not English, n = 1), and 10 selected. Overall rates of AEs (4273 [22.2/100PY]) and SAEs (827 [4.3/100PY]) were reported in the
ESPRIT registry (N = 6059). Rates of
infections (7.7-14.7/100PY) and serious
infections (<0.6-2.0/100PY) were reported in four studies. Cardiovascular-related events were reported in three studies: ≤0.1/100PY per major
cardiac event in
ESPRIT, <0.5/100PY major
cardiac events in PsoBest and serious cardiovascular events in two patients (<1%) in DERMBIO.
Malignancies were reported in three studies (any
malignancy, 0.9/100PY;
malignancies excluding non-
melanoma skin cancer [NMSC], <0.6/100PY; NMSC, 0.6-<0.5/100PY). These findings suggest that real-world safety of
adalimumab is consistent across different
psoriasis registries, which supports the existing long-term safety profile of
adalimumab from clinical studies.